After initial treatment, one participant with relapsed AML who had previously received an infusion of CD33 CAR T cells had a noticeable decrease in blast count in BM; however these AML blasts subsequently recovered, and relapse occurred 2 months post infusion (Wang et al., 2015). This evidence concerns the gene CD33 and acute myeloid leukemia.